PSNL News and Press, Personalis Inc. From 02/14/24

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at ...

2024-01-30 09:14:03 ET More on Personalis Personalis forecasts upbeat Q4 revenue outlook Personalis expects workforce reduction to extend cash runway into 2026 Read the full article on Seeking Alpha For further details see: Personalis and ClearNote Health...

Personalis to offer ClearNote’s patented Epigenomic Platform to its biopharmaceutical partners Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and ClearNote Health , Inc., a pioneer in epigenomic technologies, today unveiled an alliance through ...

NeXT Dx helps clinicians make informed, personalized cancer treatment selections and match patients with clinical trials Access to NeXT Dx expands to the 66 million Medicare and Medicare Advantage beneficiaries Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for p...

2024-01-07 17:18:52 ET More on Akoya Biosciences, Exact Sciences, etc. Guardant Health: Vast Market Opportunity, Challenging Valuation Illumina: The Divestiture Of Grail Could Unlock Significant Shareholder Value Illumina: Conditions Are Met For A Rebound Nan...

2024-01-05 09:38:15 ET More on Personalis Personalis, Inc. (PSNL) Q3 2023 Earnings Call Transcript Personalis expects workforce reduction to extend cash runway into 2026 Cancer test developer Personalis to cut 65 jobs to reduce costs Seeking Alpha’s Qu...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2023. Preliminary Fourth Quarter Revenue and Cash Balance Preliminary total company revenue i...

2023-12-21 17:17:27 ET More on Personalis Personalis, Inc. (PSNL) Q3 2023 Earnings Call Transcript Personalis expects workforce reduction to extend cash runway into 2026 Cancer test developer Personalis to cut 65 jobs to reduce costs Seeking Alpha’s Qu...

2023-12-04 11:41:08 ET More on Personalis Personalis, Inc. (PSNL) Q3 2023 Earnings Call Transcript Personalis: Collaborations Should Ignite Growth Narrative Cancer test developer Personalis to cut 65 jobs to reduce costs Personalis to issue 9.2M shares as Tem...

Workforce restructuring and recent commercial collaboration help position company for long-term success Personalis, Inc. , a leader in advanced genomics for precision oncology (Nasdaq: PSNL), disclosed a reduction in headcount impacting approximately 20% of the company’s staf...